Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

It’s free money,” I told my friend during a subway ride. “It’s as easy as watching TV in your head or playing with dolls.” ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

With the rise in adoption of agentic AI by companies for automation and increasing complexities of the newer versions, ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Microsoft Azure has been experiencing a global outage since around 1600 UTC, or 0900 PDT on Wednesday, October 29, 2025. As Azure staggers back to its feet following an hours-long outage last night, ...

Causal Machine Learning (CML) unites ML techniques with CI in order to take advantage of both approaches’ strengths. CML ...

Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...